Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 3,551 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Follow-Up Questions
DMPHF 주식의 가격 성능은 어떻습니까?
DMPHF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Dermapharm Holding SE의 주요 사업 주제나 업종은 무엇입니까?
Dermapharm Holding SE은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Dermapharm Holding SE의 시가총액은 얼마입니까?
Dermapharm Holding SE의 현재 시가총액은 $0입니다
Dermapharm Holding SE는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 7명의 분석가가 Dermapharm Holding SE에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 3명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다